The Development Landscape for Non-Alcoholic Steatohepatitis Q&A Q&A with Claudia Filozof, MD, PhD, Senior Medical Director in the Phase II-IV Cardiovascular/Metabolic Group and Richard Williams, PhD, JD, Executive Strategist, Global Regulatory Affairs Is this a good time to develop a NASH drug, and if so, why? Claudia: Yes, it’s a …